|
Congress Featured Keynote Speakers |
|
Welcome to the HUPO 6th Annual World Congress, Seoul 2007, First Newsletter. As you may know from previous HUPO congresses, each newsletter issue is designed to bring you the latest congress developments, with a special focus on the science presented and the scientists that will make this the “Can't Miss” Congress of the year. The Human Proteome Organisation (HUPO) is excited to invite you to attend and actively participate in one of the most stimulating scientific programs in Proteomics. We are confident that the HUPO 6th Annual World Congress will be a great success, providing you with the opportunity to learn and to network with leading investigators from around the world. Be sure to bookmark your agenda today and register early! |
|
Congress Newsletter April 2007 |
|
Proteomics: From Technology Development to Biomarker Applications |
|
Aaron Ciechanover |
|
Technion-Israel Institute of Technology, Haifa, Israel |
|
The Ubiquitin Proteolytic System: From Basic Mechanisms through Human Diseases and onto Drug Targeting. |
|
it was known that proteins do turn over, the large extent and high specificity of the process - whereby distinct proteins have half-lives that range from a few minutes to several days - was not appreciated. The discovery of the lysosome by Christian de Duve did not significantly change this view, as it was clear that this organelle is involved mostly in the degradation of extracellular proteins, and their proteases cannot be substrate-specific. The discovery of the complex cascade of the ubiquitin pathway revolutionized the field. It is clear now that degradation of cellular proteins is a highly complex, temporally controlled, and tightly regulated process that plays major roles in a variety of basic pathways during cell life and death, and in health and disease. With the multitude of substrates targeted, and the myriad processes involved, it is not surprising that aberrations in the pathway are implicated in the pathogenesis of many diseases, certain malignancies and neurodegeneration among them. Degradation of a protein via the ubiquitin/proteasome pathway involves two successive steps: (a) conjugation of multiple ubiquitin moieties to the substrate, and (b) degradation of the tagged protein by the downstream 26S proteasome complex. Despite intensive research, the unknown still exceeds what we currently know on intracellular protein degradation, and major key questions remain unsolved. Among these are the modes of specific and timed recognition for the degradation of the many substrates, and the mechanisms that underlie aberrations in the system that lead to pathogenesis of diseases. The recent discovery of modification by ubiquitin-like proteins along with identification of “non-canonical” polyubiquitin chains that serve non-proteolytic functions, have broadened the scope of the system beyond proteolysis and set new challenges in for biologists and proteomic experts. Major challenges in the field are clearly (i) identification of the cellular proteins tagged by ubiquitin and ubiquitin-like proteins, (ii) identification of the downstream elements recognized by these chains, and (iii) deciphering the structure of the different ubiquitin and ubiquitin-like chains that tag the different proteins. |
|
Between the sixties and eighties, most life scientists focused their attention on studies of nucleic acids and the translation of the coded information. Protein degradation was a neglected area, considered to be a non-specific, dead-end process. While |
|
Kurt Wüthrich |
|
Co-Sponsored by |
|
& |
|
ETH, Zürich, Switzerland |
|
Co-Sponsored by |
|
& |
|
Co-Sponsored by |
|
& |
|
Congress Sponsors |
|
HUPO Initiatives Sponsor |
Saturday, October 6, 2007, 9:00 AM - 5:15 PM09:00 - 09:05 Welcome Address; Angelika Görg, MunichTechnical University, Germany Chair, HUPO Education Commitee;
09:05 - 10:00 2-D Electrophoresis; Angelika Görg, MunichTechnical University, Germany
10:00 - 11:00 Sample Preparation/Prefractionation for Proteomics; Richard Simpson, Ludwig Institute, Sydney, Australia
11:00 - 12:00 MudPIT; Mike MacCoss, University of Washington, Seattle, USA
12:00 - 13:00 LUNCH
13:00 -14.00 Antibodies; Matthias Uhlen, Royal Institute of Technology, Stockholm, Sweden 14:00 - 15:00 MALDI & ESI Mass Spectrometry; Peter Roepstorff, University of Southern Denmark, Odense, Denmark
15.00 - 15:15 COFFEE
15:15 - 16:15 PTM-Proteomics; Ole N. Jensen, University of Southern Denmark, Odense, Denmark
16.15 - 17:15 Bioinformatics; Henning Hermjakob, EBI, EMBL Outstation, Hinxton, UK |
|
EDUCATION DAY |
|
CLINICAL DAY |
Sunday, October 7, 2007, 9:00 AM - 5:00 PM
Co-chairs: Sam Hanash & Choon-Sik Park
· Biofluids Proteomics: Approach 1 by John Bergeron, Montreal, Canada Immunodepletion, 1-D gel, QTOF
2 by Wiltfang Jens, Erlangen, Germany +/- Immunodepletion reverse phase, Medium 2D DIGE, MALDI
3 by Helmut Meyer, Bochum, Germany No depletion, Big DIGE, 2D gel, MALDI
4 by Xiaohong Qian, Beijing, China Immunodepletion, Isotopic labeling + mudpit, LTQ FT
5 by Young-Ki Paik, Seoul, Korea iTraQ, MALDI-TOF/TOF
· Application of Microarrays to Clinical Proteomics Mike Snyder, Yale University, USA Thomas Joos, University of Tuebingen, Germany Brian Haab, Van Andel Research Institute, USA Dolores Cahill, University College, Dublin
· NCI Forum on Clinical Proteomics: Voyage from Proteomics to Cancer Diagnostics: Are We There Yet?
Clinical Proteomics: A Reality Check: Sudhir Srivastava, NCI, USA
The Nuts and Bolts of Clinical Proteomics: Jacob Kagan, NCI and Karin Rodland, Pacific Northwest National Laboratory, USA
Are Diagnostic Laboratories Prepared to Adopt Proteomics as Diagnostic Tools: Daniel Chan, Johns Hopkins University, USA
Have the International Programs in Clinical Proteomics Lost Directions: Sam Hanash, Fred Hutchinson Cancer Center, USA
Panel Discussions: Reality Checks : Panelists to be announced.
Forecast 1: The application of proteomic technologies to potential markers, such as antigens, autoantibodies, metabolites, etc. will have relevance to all health care settings (cancer) in the decade ahead. What captures reagents, tools and technologies will be implemented for clinical application? Forecast 2: Biomarker discovery and drug development will be accelerated and fundamentally redesigned in the decade ahead as a result of progress in the field of proteomics . Are we on track? Forecast 3: Between now and 2020, diagnostics and treatment will evolve to a higher level of individualization such that therapeutic selection will be precisely tailored to each patient’s (proteomic) profiles. Are we making progress in that direction? |
|
As of April 25, 2007—for the latest please visit the congress website - Listed in Alphabetical Order-Keynote LecturesAaron Ciechanover, Technion-Israel Institute of Technology, Israel Kurt Wüthrich, ETH Zurich, Switzerland
Plenary Lectures Ruedi Aebersold, Institute for Molecular System Biology, USA Rolf Apweiler, European Molecular Biology Laboratory, UK John J. M. Bergeron, McGill University, Canada Julio E. Celis, Danish Centre for Translational Breast Cancer Research, Denmark Sam Hanash, Fred Hutchinson Cancer Research Center, USA Sung-Hou Kim, University of California, Berkeley, USA Richard Smith, Pacific Northwest National Laboratory, USA Mike Snyder, Yale University, USA Mathias Uhlen, Royal Institute of Technology, KTH, Sweden John R. Yates III, Scripps Research Institute, USA
Symposium (partial list out of 80 invited speakers) Natalie Ahn, University of Colorado, USA Ron Appel, Swiss Institute of Bioinformatics, Switzerland Alexander Archakov, Institute of Biomedical Chemistry, Russia Ronald Beavis, Beavis Informatics Ltd., Canada Carl Borrebaeck, Lund University, Sweden Ralph Bradshaw, University of California, Irvine, USA Dolores Cahill, UCD Conway Institute, University College, Dublin, Ireland Maxey Ching Ming Chung, National University of Singapore Stuart Cordwell, University of Sydney, Australia Catherine Costello, School of Medicine, Boston University, USA Michael Dunn, University College Dublin, Ireland Catherine Fenselau, University of Maryland, USA Michael Fountoulakis, Hellenic Proteomics Society, Greece Angelika Gorg, Munich Technical University, Germany Brian Haab, Van Andel Research Institute, USA William Hancock, Northeastern University, USA Fuchu He, Beijing Proteome Research Center, China Albert Heck, The Netherlands Proteomics Center Mike Hengatner, Institute of Molecular Biology, University of Zurich, Switzerland Henning Hermjakob, European Bioinformatics Institute, UK Hubert Hondermarck, Universite des Sciences et Technologies de Lille, France Ole Jensen, University of Southern Denmark Manohar John, Massachusetts General Hospital, USA Thomas Joos, Natural and Medical Science Institute, University of Tuebingen, Germany Setsuko Komatsu, National Institute of Agrobiological Sciences, Japan Martin Larsen, Odense University, Denmard Weontae Lee, Yonsei University, Korea Bong Hee Lee, Gacheon Medical University, Korea Mike MacCoss, University of Washington, USA Rune Matthiesen, CIC BIOGUNE, Spain Martin McIntosh, Fred Hutchinson Cancer Research Center, USA Helmut Meyer, University of Bochum, Germany Kazuyuki Nakamura, Yamaguchi University, Japan |
